Analyzing blood samples to understand Hodgkin lymphoma prognosis
Prognostic Significance of Circulating Tumor DNA in Hodgkin Lymphoma
This study is trying to see if analyzing blood samples for certain mutations and the Epstein-Barr virus can help doctors better understand how Hodgkin lymphoma behaves and improve treatment decisions for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Interni hematologicka klinika FNKV Research network |
| Drugs / interventions | brentuximab, nivolumab, chemotherapy |
| Locations | 5 sites (Hradec Králové and 4 other locations) |
| Trial ID | NCT06263530 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on analyzing circulating tumor DNA (ctDNA) in patients with classical Hodgkin lymphoma (cHL) to identify specific somatic mutations. Blood samples will be collected at various treatment stages, including diagnosis and after chemotherapy, to correlate these mutations with treatment responses and tumor mass. Additionally, the study will assess the presence of Epstein-Barr virus (EBV) in EBV-positive patients to further understand its role in cHL prognosis. The goal is to develop a prognostic model that can guide treatment decisions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with newly diagnosed classical Hodgkin lymphoma.
Not a fit: Patients who do not sign the informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and personalized treatment strategies for patients with Hodgkin lymphoma.
How similar studies have performed: Other studies have shown promise in using ctDNA for prognostic purposes in various cancers, suggesting a potential for success in this approach for Hodgkin lymphoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥ 18 years with newly histologically confirmed classical Hodgkin lymphoma (cHL) will be enrolled * signing the informed consent Exclusion Criteria: * Pacients without signing the informed consent
Where this trial is running
Hradec Králové and 4 other locations
- University Hospital Hradec Kralove — Hradec Králové, Czechia (Recruiting)
- University Hospital Olomouc — Olomouc, Czechia (Recruiting)
- University Hospital Kralovske Vinohrady — Prague, Czechia (Recruiting)
- Charles University — Prague, Czechia (Active_not_recruiting)
- General University Hospital — Prague, Czechia (Recruiting)
Study contacts
- Study coordinator: Heidi Mocikova, M.D., Ph.D.
- Email: heidi.mocikova@fnkv.cz
- Phone: +420267163554
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.